期刊
CLINICAL INFECTIOUS DISEASES
卷 69, 期 7, 页码 1229-1231出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciz074
关键词
XDR-tuberculosis; delamanid resistance; bedaquiline resistance
资金
- Institute for Microbiology, Immunology and Laboratory Medicine, Helios Klinikum Emil von Behring
- SYNLAB Gauting, SYNLAB MVZ Humane Genetik
- Research Center Borstel
- German Center for Infection Research
- National Reference Laboratory for Mycobacteria
- Deutsche Forschungsgemeinschaft (German Research Foundation), Germany's Excellence Strategy [EXC 22167-390884018]
- Leibniz Science Campus EvoLUNG (Evolutionary Medicine of the Lung)
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
